Compare ADMA Biologics Inc (ADMA) vs Futu Holdings Ltd (FUTU) Price & Performance

ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.

Futu Holdings Limited (FUTU) trades at $105.31, down 3.12% on the day. The stock shows strong fundamentals with a P/E of 11.63 and robust profitability, including a net income margin of 41.83% and ROE of 28.09%. Revenue grew to $22.85B in 2025, and cash flow from operations surged to $31.0B in 2024. Technical indicators are bullish, with moving averages supporting an uptrend and key support at $103. However, recent earnings misses and a securities class action lawsuit pose significant headwinds.

The outlook for FUTU is mixed; strong financial health and analyst consensus leaning buy (58.34%) suggest potential upside, but legal risks and earnings volatility require caution. Investors should weigh solid fundamentals against regulatory and litigation overhangs that could impact near-term performance.